INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnership with Viracta Therapeutics
Phase Ib/II Clinical Trial Data Reported at 2019 Annual Meeting of the American Society of Clinical Oncology Shows High Overall Objective Response Rate (ORR) of 58% and Complete Response Rate (CR) of 33% in Relapsed/Refractory Lymphoma Patients CULVER CITY, Calif. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients
First engineered, GMP-grade, cryopreserved, off-the-shelf, bi-specific NK cell therapy to enter human clinical trials targeting CD16 and CD19 in patients with lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
View HTML
Toggle Summary NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 3, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being
View HTML
Toggle Summary NantKwest, NantCell and NantOmics to Provide Updated Preclinical and Clinical Data in Four Abstracts at Part of the American Society of Clinical Oncology Annual Meeting
Preclinical and Clinical Data Demonstrate Advanced Deployment of Precision Medicine Tools to Analyze and Potentially More Effectively Intervene with Highly Focused Therapeutic Interventions CULVER CITY, Calif. --(BUSINESS WIRE)--May 31, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage,
View HTML
Toggle Summary Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Brink Biologics, Inc. , a  NantKwest, Inc.
View HTML
Toggle Summary NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019 CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the Company has
View HTML
Toggle Summary NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK’s Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy
Completion of Phase 1 First-in-Human Trials of Cryopreserved, Off-The-Shelf haNK Cells Leads the Way to Pivotal Phase 2 Trials in Relapsed Merkel Cell Carcinoma Funding to Support INDs for First-in-Human Targeted Off-The-Shelf NK Cells (t-haNKs) with PD-L1 and CD-19 as Tumor Targets CULVER CITY,
View HTML
Toggle Summary NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During Keynote Address at Innate Killer Summit
SAN DIEGO & CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 18, 2019-- NantKwest ( Nasdaq:NK ), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company’s Chairman & CEO, Dr. Patrick Soon-Shiong , will be giving a keynote address at the Innate Killer
View HTML
Toggle Summary NantKwest to Participate at the Cowen & Company 39th Annual Health Care Conference
CULVER CITY, CA.- March 10, 2019 –  NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating and conducting one-on-one meetings at the Cowen 39th Annual Health Care Conference World Immunotherapy Congress
View HTML
Toggle Summary NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell Therapeutics
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate for Multiple Myeloma, with an Option for up to Five Additional CAR Targeting Sequences SAN DIEGO --(BUSINESS WIRE)--Mar. 4, 2019-- NantKwest, Inc. (Nasdaq:NK) , a leading clinical-stage Natural Killer (NK)
View HTML

Data Provided by Refinitiv. Minimum 15 minutes delayed.